Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Liminal BioSciences Inc. PFSCF


Primary Symbol: LMNL

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.


NDAQ:LMNL - Post by User

Bullboard Posts
Comment by fdeslogeson Mar 02, 2016 8:12am
372 Views
Post# 24611863

RE:What next. Casual thread...

RE:What next. Casual thread...I may be wrong , but my gut feeling is that we won't hear of 1402 anymore.
I've never been answered directly either, for some strategic reasons I guess, but the general feeling from the different answers is that 4050 and others cousins molecules have something that makes them more valuable than 1402. So I expect that some other molecule will take the relay of 1402 for CIA, but only a couple of years from now. Once/if the lowest (and largest) hanging fruits have been reaped from the 4050 tree, and ProMetic is cash free to pursue more controversial venture all by itself.

Because anemia have proven to be a difficult thing to sell around, in the aftermath of the incumbent EPO mis-behavior, and ProMetic didn't want to fight that face wind when other so easier options where almost falling on our plate all by themselves.

That will obviously change if/when the first billions from 4050 ends up materializing...

IMHO
FD
Bullboard Posts

USER FEEDBACK SURVEY ×

Be the voice that helps shape the content on site!

At Stockhouse, we’re committed to delivering content that matters to you. Your insights are key in shaping our strategy. Take a few minutes to share your feedback and help influence what you see on our site!

The Market Online in partnership with Stockhouse